-
Mashup Score: 0Biosimilar MB02-DM Demonstrates Bioequivalence to Bevacizumab - 1 year(s) ago
Statistical analysis showed no differences between each pairwise comparison of the bevacizumab biosimilars, MB02-SP and MB02-DM, and the reference drug.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Biosimilar MB02-DM Demonstrates Bioequivalence to Bevacizumab - 1 year(s) ago
Statistical analysis showed no differences between each pairwise comparison of the bevacizumab biosimilars, MB02-SP and MB02-DM, and the reference drug.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet-
Statistical analysis showed no differences between each pairwise comparison of the #bevacizumab #biosimilars, MB02-SP and MB02-DM, and the reference drug. https://t.co/o6EjPe4YIF https://t.co/O3RxrEzD5T
-
-
Mashup Score: 2
Findings from the patient-reported outcomes analysis of the phase 3 KEYNOTE-826 trial support the benefit of pembrolizumab in patients with recurrent, persistent, or metastatic cervical cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The addition of #pembrolizumab to chemotherapy with/without #bevacizumab did not negatively affect health-related QOL in patients with recurrent, persistent, or metastatic cervical cancer. #gyncsm https://t.co/JZWbNIaaCM
-
-
Mashup Score: 0
During a Targeted Oncology™ Case-Based Roundtable™ event, Paul D. DiSilvestro, MD, discussed the updated results of the PAOLA-1 trial of bevacizumab followed by olaparib maintenance in patients with advanced ovarian cancer. This is the third of 3 articles based on this event.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Paul D. DiSilvestro, MD, discussed the updated results of the PAOLA-1 trial of #bevacizumab followed by #olaparib maintenance in patients with advanced #ovariancancer. | @BrownMedicine https://t.co/9ymHZOY1M6
-
-
Mashup Score: 0
Intravitreal bevacizumab may contribute to the need for longer ventilation support and a reduced chance of becoming ventilator-free among preterm infants with bronchopulmonary dysplasia, according to a study published in CHEST.Intravitreal bevacizumab (IVB) is an anti-vascular endothelial growth factor (VEGF) antibody that is used to treat retinopathy of prematurity (ROP), a main contributor of
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
Infants who underwent intravitreal #bevacizumab treatment had an older postmenstrual age (PMA) when becoming ventilator-free, an older PMA at discharge and longer hospitalization, according to study results published in @journal_CHEST. https://t.co/tecETTmjYP
-
-
Mashup Score: 0
Intravitreal bevacizumab may contribute to the need for longer ventilation support and a reduced chance of becoming ventilator-free among preterm infants with bronchopulmonary dysplasia, according to a study published in CHEST.Intravitreal bevacizumab (IVB) is an anti-vascular endothelial growth factor (VEGF) antibody that is used to treat retinopathy of prematurity (ROP), a main contributor of
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
According to a study published in @journal_CHEST, intravitreal #bevacizumab may contribute to the need for longer #ventilation support and a reduced chance of becoming ventilator-free among preterm infants with bronchopulmonary dysplasia. https://t.co/tecETTmjYP
-
-
Mashup Score: 0
The addition of bevacizumab did not seem to increase the benefit of FOLFIRI with regard to overall survival. FOLFIRI could be considered as a standard second-line treatment in patients with gastroenteropancreatic neuroendocrine carcinoma.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Online First: #Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line #chemotherapy in patients with advanced #neuroendocrinecarcinoma (PRODIGE 41-BEVANEC): a randomised phase 2 trial https://t.co/rdfIKs3Qel
-
-
Mashup Score: 0New Standard of Care for Refractory Metastatic Colorectal Cancer - 1 year(s) ago
Significant improvement in OS, PFS with addition of bevacizumab to trifluridine/tipiracil
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
Survival in treatment-refractory metastatic #colorectalcancer improved by more than 3 months in patients who received #bevacizumab (Avastin) in addition to #chemotherapy, reported @TaberneroJosep, MD, at #ASCOGI2023. https://t.co/0Gf4x6Kmom @DocDustyD @medpagetoday #OncTwitter
-
-
Mashup Score: 0
Trifluridine-tipiracil plus bevacizumab was not superior to capecitabine plus bevacizumab but presented no new safety concerns in patients with unresectable metastatic colorectal cancer who are ineligible for intensive treatment. “The standard first-line treatment for patients with unresectable metastatic colorectal cancer is full-dose doublet or triplet chemotherapy with or without
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI from @LancetGastroHep: #Trifluridinetipiracil plus #bevacizumab ‘feasible alternative’ for unresectable #CRC #GITwitter #MedTwitter #oncology @HemOncToday https://t.co/kDL7lRLLiE
-
-
Mashup Score: 1
Trifluridine-tipiracil plus bevacizumab was not superior to capecitabine plus bevacizumab but presented no new safety concerns in patients with unresectable metastatic colorectal cancer who are ineligible for intensive treatment. “The standard first-line treatment for patients with unresectable metastatic colorectal cancer is full-dose doublet or triplet chemotherapy with or without
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#Trifluridinetipiracil plus #bevacizumab was not superior to #capecitabine plus bevacizumab but presented no new safety concerns in patients with unresectable metastatic #colorectalcancer who are ineligible for intensive treatment @LancetGastroHep https://t.co/kDL7lRLLiE
-
Statistical analysis showed no differences between each pairwise comparison of the #bevacizumab #biosimilars, MB02-SP and MB02-DM, and the reference drug: https://t.co/16nPpB1XBB